machine learning
The company continues to build validation data and believes its lower cost proposition can help it gain leverage in the European market where molecular tests are not reimbursed.
The test assigns a pancreatic cancer subtype based on the expression of 16 genes measured using an array.
Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.
The machine learning framework extracts features from digital pathology slides to diagnose and predict multiple types of cancer.
The firm is shifting its focus away from the Paige Platform ecosystem and toward incorporating its AI-based tests onto other companies' digital pathology systems.
Aug 22, 2024
Feb 7, 2024
Mar 30, 2023